Status:
UNKNOWN
Assessing Ketorolac (Toradol) at Oocyte Retrieval
Lead Sponsor:
Shady Grove Fertility Reproductive Science Center
Conditions:
Infertility
Infertility, Female
Eligibility:
FEMALE
18-45 years
Phase:
PHASE1
Brief Summary
To determine if a nonsteroidal anti-inflammatory drug (NSAID), Ketorolac (Toradol), can improve pain control and decrease narcotic use after undergoing egg retrieval.
Detailed Description
Postoperative pain control is an essential component to any surgical procedure. Surgery represents a time during which opioid-naïve patients may be exposed to narcotics, risking opioid related complic...
Eligibility Criteria
Inclusion
- Signed informed consent
- Females over 18 years of age who are scheduled to undergo oocyte retrieval
- Patients must be able to read and understand written English or have an appropriate certified medical translator available.
- Standard eligibility criteria to undergo IVF and embryo transfer at Shady Grove
Exclusion
- Known allergy to ketorolac
- Those with known medical conditions precluding them from ketorolac use (active peptic ulcer disease, recent or history of hemorrhage or perforation, known renal or hepatic insufficiency, suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, bleeding disorders, recent myocardial infarction, or stroke.)
- BMI ≥ 40 kg/m2
- History of substance abuse
- Chronic opioid use
- Transabdominal oocyte retrieval
Key Trial Info
Start Date :
August 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06026553
Start Date
August 10 2022
End Date
January 1 2025
Last Update
September 7 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Shady Grove Fertility Reproductive Science Center
Rockville, Maryland, United States, 20850
2
Shady Grove Fertility Reproductive Science Center
Fairfax, Virginia, United States, 22031